X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
male (35) 35
female (34) 34
middle aged (30) 30
adult (23) 23
aged (23) 23
index medicus (21) 21
hematology (14) 14
risk factors (14) 14
diagnosis (11) 11
prospective studies (11) 11
double-blind method (10) 10
thrombosis (10) 10
treatment outcome (10) 10
aged, 80 and over (9) 9
prevention (9) 9
thromboembolism (9) 9
venous thrombosis (8) 8
article (7) 7
medicine, general & internal (7) 7
recurrence (7) 7
time factors (7) 7
antiphospholipid antibodies (6) 6
chemotherapy (6) 6
cohort studies (6) 6
peripheral vascular disease (6) 6
abridged index medicus (5) 5
anticoagulants (5) 5
anticoagulants - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
clinical trials (5) 5
disease (5) 5
dose-response relationship, drug (5) 5
follow-up studies (5) 5
hemorrhage - chemically induced (5) 5
vein thrombosis (5) 5
venous thromboembolism (5) 5
warfarin (5) 5
warfarin - administration & dosage (5) 5
warfarin - adverse effects (5) 5
acute myeloid leukemia (4) 4
anticoagulants - adverse effects (4) 4
anticoagulants - therapeutic use (4) 4
blood coagulation, fibrinolysis and cellular haemostasis (4) 4
cancer (4) 4
care and treatment (4) 4
d-dimer (4) 4
deep venous thrombosis (4) 4
deep-vein thrombosis (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
leukemia, myeloid, acute - drug therapy (4) 4
molecular-weight heparin (4) 4
odds ratio (4) 4
pulmonary embolism (4) 4
research (4) 4
rheumatology (4) 4
risk (4) 4
stockings, compression (4) 4
thromboembolism - prevention & control (4) 4
activated protein c resistance (3) 3
acute disease (3) 3
acute nonlymphocytic leukemia (3) 3
antibodies, antiphospholipid - blood (3) 3
anticardiolipin antibodies (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
canada (3) 3
deep vein thrombosis (3) 3
dosage and administration (3) 3
embolisms (3) 3
evaluation (3) 3
hematology, oncology and palliative medicine (3) 3
hemic and lymphatic diseases (3) 3
human health and pathology (3) 3
in-vitro (3) 3
international normalized ratio (3) 3
kaplan-meier estimate (3) 3
life sciences (3) 3
medical research (3) 3
myelodysplastic syndrome (3) 3
oncology (3) 3
original (3) 3
outpatients (3) 3
patients (3) 3
postthrombotic syndrome - etiology (3) 3
pulmonary embolism - prevention & control (3) 3
quality of life (3) 3
quebec (3) 3
risk assessment (3) 3
secondary prevention (3) 3
studies (3) 3
surgery (3) 3
systemic-lupus-erythematosus (3) 3
therapy (3) 3
thromboembolism - blood (3) 3
thrombophlebitis (3) 3
united states (3) 3
vascular diseases - immunology (3) 3
venous thrombosis - blood (3) 3
venous thrombosis - diagnosis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9920, pp. 880 - 888
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2017, Volume 12, Issue 1, p. e0169268
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2003, Volume 349, Issue 7, pp. 631 - 639
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2009, Volume 27, Issue 28, pp. 4741 - 4746
Journal Article
Leukemia Research Reports, ISSN 2213-0489, 2014, Volume 3, Issue 2, pp. 58 - 61
Abstract Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid... 
Hematology, Oncology and Palliative Medicine | Pathology | Myelodysplastic syndrome (MDS) | Safety | Alisertib | Aurora A kinase inhibitor | Acute myeloid leukemia (AML)
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/1999, Volume 340, Issue 12, pp. 901 - 907
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 230 - 230
Abstract Introduction: Despite recent advances in available treatments, chronic lymphocytic leukemia (CLL) remains an incurable disease, and the vast majority... 
Journal Article
JAMA internal medicine, ISSN 2168-6106, 08/2019, Volume 179, Issue 11, p. 1469
Patients with atrial fibrillation (AF) who use a direct oral anticoagulant (DOAC) and request elective surgery or procedure present a common clinical situation... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2009, Volume 147, Issue 4, pp. 507 - 514
Summary MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia... 
MGCD0103 | chronic lymphocytic leukaemia | epigenetics | histone deacetylase inhibitors | Epigenetics | Chronic lymphocytic leukaemia | Histone deacetylase inhibitors | APOPTOSIS | IN-VITRO | METHYLATION | ACTIVATION | B-CELL | VIVO | HEMATOLOGY | DEPSIPEPTIDE FR901228 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Benzamides - adverse effects | Antibodies, Monoclonal, Murine-Derived | Drug Administration Schedule | Pyrimidines - administration & dosage | Rituximab | Histone Deacetylases - metabolism | Treatment Outcome | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Chromosome Aberrations | Pyrimidines - adverse effects | Aged | Histone Deacetylase Inhibitors - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Histone Deacetylase Inhibitors - adverse effects | Medicine, Experimental | Clinical trials | Medical research | Universities and colleges | Index Medicus | Chronic lymphocytic leukemia
Journal Article